| First Author | Liu CL | Year | 2020 |
| Journal | Front Endocrinol (Lausanne) | Volume | 11 |
| Pages | 621944 | PubMed ID | 33613454 |
| Mgi Jnum | J:306848 | Mgi Id | MGI:6718225 |
| Doi | 10.3389/fendo.2020.621944 | Citation | Liu CL, et al. (2020) Quinolinate Phosphoribosyltransferase Promotes Invasiveness of Breast Cancer Through Myosin Light Chain Phosphorylation. Front Endocrinol (Lausanne) 11:621944 |
| abstractText | Perturbed Nicotinamide adenine dinucleotide (NAD(+)) homeostasis is involved in cancer progression and metastasis. Quinolinate phosphoribosyltransferase (QPRT) is the rate-limiting enzyme in the kynurenine pathway participating in NAD(+) generation. In this study, we demonstrated that QPRT expression was upregulated in invasive breast cancer and spontaneous mammary tumors from MMTV-PyVT transgenic mice. Knockdown of QPRT expression inhibited breast cancer cell migration and invasion. Consistently, ectopic expression of QPRT promoted cell migration and invasion in breast cancer cells. Treatment with QPRT inhibitor (phthalic acid) or P2Y11 antagonist (NF340) could reverse the QPRT-induced invasiveness and phosphorylation of myosin light chain. Similar reversibility could be observed following treatment with Rho inhibitor (Y16), ROCK inhibitor (Y27632), PLC inhibitor (U73122), or MLCK inhibitor (ML7). Altogether, these results indicate that QPRT enhanced breast cancer invasiveness probably through purinergic signaling and might be a potential prognostic indicator and therapeutic target in breast cancer. |
